Edris Badreddin 4

What Happened
Edris Badreddin, a director of Edgewise Therapeutics (EWTX), exercised multiple option/derivative awards on Jan 21, 2026 and immediately sold the resulting shares in open-market transactions. Total cash paid to exercise the options was about $170,265; total gross proceeds from the sales were about $3.40 million (average sale price reported as $29.44). The filing shows matching derivative conversion/disposition entries recorded at $0 (non-cash/recording entries).

• Exercises (all Jan 21, 2026; amounts reflect exercise cost shown on Form 4):
  • 13,690 shares @ $0.39 — $5,339 exercise cost
  • 17,236 shares @ $0.64 — $11,031
  • 10,463 shares @ $1.93 — $20,194
  • 66,477 shares @ $1.93 — $128,301
  • 7,605 shares @ $0.71 — $5,400
• Same-day sales (open market; proceeds shown):
  • 13,690 shares — $403,034
  • 17,236 shares — $507,428
  • 7,605 shares — $223,891
  • 10,463 shares — $308,031
  • 66,477 shares — $1,957,083

Key Details

• Transaction date: January 21, 2026; Form 4 filed January 23, 2026 (appears timely).
• Sale pricing: average $29.44; trades occurred across $29.00–$29.77 per footnote.
• Total proceeds from sales: ≈ $3,399,467; total exercise outlay: ≈ $170,265.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: Sales were executed pursuant to a Rule 10b5-1 trading plan adopted Sept 24, 2025. The filing discloses the average price and offers to provide per-trade prices on request.
• The Form shows separate derivative “disposed” entries at $0, which are the reporting records tied to conversion/exercise of the derivative instruments.

Context

• This is effectively a same-day exercise and sell (often called a cashless exercise/sell-to-cover pattern): options were exercised at low strike prices and the resulting shares were sold immediately, generating net cash proceeds for the reporting person.
• Such sales under an established 10b5-1 plan are typically pre-arranged and do not, by themselves, indicate the insider’s current view of the company’s prospects.
• No indication in the filing that this is a >10% owner transaction; reporting person is a company director.